Neurologix and Diamyd have signed the license agreement in August 2006. It is a running agreement with milestone payments and royalty on sales.
Elisabeth Lindner, president and CEO at Diamyd, said: “These are very positive news for Diamyd, and the fact that GAD can be used within additional therapeutic areas, not only within diabetes, predicts an exciting future for us. That GAD is also used for neurological disorders opens up for further new licensing possibilities.”